|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Laboratory of Molecular Pharmacology, Section of Theoretical and Receptor Pharmacology, Department of Pharmacological Sciences, University of Milan, Milan, Italy (G.E.R., V.C.); and Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.)
Despite extensive study of heptahelical G protein-coupled receptors (GPCRs), the precise mechanism of G protein activation is unknown. The role of one highly conserved stretch of residues, the amino acids glutamic acid/aspartic acidargininetyrosine (i.e., the E/DRY motif), has received considerable attention with respect to regulating GPCR conformational states. In the consensus view, glutamic acid/aspartic acid maintains the receptor in its ground state, because mutations frequently induce constitutive activity (CA). This hypothesis has been confirmed by the rhodopsin ground-state crystal structure and by computational modeling approaches. However, some class A GPCRs are resistant to CA, suggesting alternative roles for the glutamic acid/aspartic acid residue and the E/DRY motif. Here, we propose two different subgroups of receptors within class A GPCRs that make different use of the E/DRY motif, independent of the G protein type (Gs, Gi, or Gq) to which the receptor couples. In phenotype 1 receptors, nonconservative mutations of the glutamic acid/aspartic acidarginine residues, besides inducing CA, increase affinity for agonist binding, retain G protein coupling, and retain an agonist-induced response. In contrast, in second phenotype receptors, the E/DRY motif is more directly involved in governing receptor conformation and G protein coupling/recognition. Hence, mutations of the glutamic acid/aspartic acid residues do not induce CA. Conversely, nonconservative mutations of the arginine of the E/DRY motif always impair agonist-induced receptor responses and, generally, reduce agonist binding affinity. Thus, it is essential to look beyond the rhodopsin ground-state model of conformational activation to clarify the role of this highly conserved triplet in GPCR activation and function.
Address correspondence to: Dr. G. Enrico Rovati, Laboratory of Molecular Pharmacology, Department of Pharmacological Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy. E-mail: genrico.rovati{at}unimi.it
This article has been cited by other articles:
![]() |
E. Peverelli, A. G. Lania, G. Mantovani, P. Beck-Peccoz, and A. Spada Characterization of Intracellular Signaling Mediated by Human Somatostatin Receptor 5: Role of the DRY Motif and the Third Intracellular Loop Endocrinology, July 1, 2009; 150(7): 3169 - 3176. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Ye, F. Boulay, J. M. Wang, C. Dahlgren, C. Gerard, M. Parmentier, C. N. Serhan, and P. M. Murphy International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family Pharmacol. Rev., June 1, 2009; 61(2): 119 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Auchampach, L. M. Kreckler, T. C. Wan, J. E. Maas, D. van der Hoeven, E. Gizewski, J. Narayanan, and G. E. Maas Characterization of the A2B Adenosine Receptor from Mouse, Rabbit, and Dog J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 2 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kocan, H. B. See, N. G. Sampaio, K. A. Eidne, B. J. Feldman, and K. D. G. Pfleger Agonist-Independent Interactions between {beta}-Arrestins and Mutant Vasopressin Type II Receptors Associated with Nephrogenic Syndrome of Inappropriate Antidiuresis Mol. Endocrinol., April 1, 2009; 23(4): 559 - 571. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. O. Dror, D. H. Arlow, D. W. Borhani, M. O. Jensen, S. Piana, and D. E. Shaw Identification of two distinct inactive conformations of the {beta}2-adrenergic receptor reconciles structural and biochemical observations PNAS, March 24, 2009; 106(12): 4689 - 4694. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Strachan, D. J. Sheffler, B. Willard, M. Kinter, J. G. Kiselar, and B. L. Roth Ribosomal S6 Kinase 2 Directly Phosphorylates the 5-Hydroxytryptamine 2A (5-HT2A) Serotonin Receptor, Thereby Modulating 5-HT2A Signaling J. Biol. Chem., February 27, 2009; 284(9): 5557 - 5573. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Sum, I. G. Tikhonova, S. Costanzi, and M. C. Gershengorn Two Arginine-Glutamate Ionic Locks Near the Extracellular Surface of FFAR1 Gate Receptor Activation J. Biol. Chem., February 6, 2009; 284(6): 3529 - 3536. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang, H. Zhao, Y. Qiu, H. H. Loh, and P.-Y. Law Src Phosphorylation of {micro}-Receptor Is Responsible for the Receptor Switching from an Inhibitory to a Stimulatory Signal J. Biol. Chem., January 23, 2009; 284(4): 1990 - 2000. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Chung, T. R. Webb, L. F. Chan, S. N. Cooray, L. A. Metherell, P. J. King, J. P. Chapple, and A. J. L. Clark The Majority of Adrenocorticotropin Receptor (Melanocortin 2 Receptor) Mutations Found in Familial Glucocorticoid Deficiency Type 1 Lead to Defective Trafficking of the Receptor to the Cell Surface J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4948 - 4954. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Wacker, D. B. Feller, X.-B. Tang, M. C. DeFino, Y. Namkung, J. S. Lyssand, A. J. Mhyre, X. Tan, J. B. Jensen, and C. Hague Disease-causing Mutation in GPR54 Reveals the Importance of the Second Intracellular Loop for Class A G-protein-coupled Receptor Function J. Biol. Chem., November 7, 2008; 283(45): 31068 - 31078. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Sarkar, I. Dodevski, M. Kenig, S. Dudli, A. Mohr, E. Hermans, and A. Pluckthun From the Cover: Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity PNAS, September 30, 2008; 105(39): 14808 - 14813. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Proulx, B. J. Holleran, A. A. Boucard, E. Escher, G. Guillemette, and R. Leduc Mutational Analysis of the Conserved Asp2.50 and ERY Motif Reveals Signaling Bias of the Urotensin II Receptor Mol. Pharmacol., September 1, 2008; 74(3): 552 - 561. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Artigas, A. Gonzalez, E. Riquelme, C. A. Carvajal, A. Cattani, A. Martinez-Aguayo, A. M. Kalergis, T. Perez-Acle, and C. E. Fardella A Novel Adrenocorticotropin Receptor Mutation Alters Its Structure and Function, Causing Familial Glucocorticoid Deficiency J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3097 - 3105. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Pang, J. Dong, and P. Thomas Estrogen Signaling Characteristics of Atlantic Croaker G Protein-Coupled Receptor 30 (GPR30) and Evidence It Is Involved in Maintenance of Oocyte Meiotic Arrest Endocrinology, July 1, 2008; 149(7): 3410 - 3426. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hase, T. Yokomizo, T. Shimizu, and M. Nakamura Characterization of an Orphan G Protein-coupled Receptor, GPR20, That Constitutively Activates Gi Proteins J. Biol. Chem., May 9, 2008; 283(19): 12747 - 12755. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tokunaga, B. Matsuura, M. Dong, L. J. Miller, T. Ueda, S. Furukawa, Y. Hiasa, and M. Onji Mutational analysis of predicted intracellular loop domains of human motilin receptor Am J Physiol Gastrointest Liver Physiol, February 1, 2008; 294(2): G460 - G466. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Johnston and D. P. Siderovski Receptor-Mediated Activation of Heterotrimeric G-Proteins: Current Structural Insights Mol. Pharmacol., August 1, 2007; 72(2): 219 - 230. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Tao, S. Nandadasa, P. D. McCrea, J. Heasman, and C. Wylie G-protein-coupled signals control cortical actin assembly by controlling cadherin expression in the early Xenopus embryo Development, July 15, 2007; 134(14): 2651 - 2661. [Abstract] [Full Text] [PDF] |
||||